Citation: Annals of Translational Medicine. 6(20):409, 2018 Oct..Journal: Annals of translational medicine.Published: ; 2018ISSN: 2305-5839.Full author list: Black CK; Termanini KM; Aguirre O; Hawksworth JS; Sosin M.UI/PMID: 30498736.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment(s): Surgery/TransplantationActivity type: Journal Article.Medline article type(s): Journal Article | ReviewOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.21037/atm.2018.09.68 (Click here)Abbreviated citation: Ann. transl. med.. 6(20):409, 2018 Oct.Abstract: Solid organ transplantation (SOT) has emerged from an experimental approach in the 20<sup>th</sup> century to now being an established and practical definitive treatment option for patients with end-organ dysfunction. The evolution of SOT has seen the field progress rapidly over the past few decades with incorporation of a variety of solid organs-liver, kidney, pancreas, heart, and lung-into the donor pool. New advancements in surgical technique have allowed for more efficient and refined multi-organ procurements with minimal complications and decreased ischemic injury events. Additionally, immunosuppression therapy has also seen advancements with the expansion of immunosuppressive protocols to dampen the host immune response and improve short and long-term graft survival. However, the field of SOT faces new barriers, most importantly the expanding demand for SOT that is outpacing the current supply. Allocation protocols have been developed in an attempt to address these concerns. Other avenues for SOT are also being explored to increase the donor pool, including split-liver donor transplants, islet cell implantation for pancreas transplants, and xenotransplantation. The future of SOT is bright with exciting new research being explored to overcome current obstacles.